Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from...

Area of Science:

• Neurology
• Neuroscience
• Medical Imaging

Background:

• Neurodegenerative disorders, including Alzheimer and Parkinson disease, are increasing globally, posing significant health and economic burdens.
• Abnormal protein accumulation in the brain is a key factor in neurotoxicity and network disruption in these diseases.
• Current therapeutic strategies targeting proteinopathies face challenges in early diagnosis, disease progression variability, and efficacy measurement.

Approach:

• This review examines the use of Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) imaging.
• These scintigraphic imaging modalities offer high specificity for interrogating pathophysiologic processes like protein deposition.
• The focus is on the implementation of these imaging biomarkers in clinical trials for neurodegenerative disorders.

Key Points:

• Accurate early diagnosis and identification of at-risk, premanifest individuals are critical for effective treatment of neurodegenerative diseases.
• Imaging biomarkers like PET and SPECT are essential tools for assessing disease progression and treatment efficacy.
• These techniques enable the study of underlying pathology, such as specific protein deposits in the brain.

Conclusions:

• Scintigraphic imaging plays a vital role in advancing the development of therapeutics for neurodegenerative diseases.
• The application of PET and SPECT imaging holds significant implications for the future management of central nervous system disorders.
• Continued research and implementation of imaging biomarkers will accelerate drug development for proteinopathies and other CNS conditions.